|
Gene: TNC |
Gene summary for TNC |
Gene summary. |
Gene information | Species | Human | Gene symbol | TNC | Gene ID | 3371 |
Gene name | tenascin C | |
Gene Alias | 150-225 | |
Cytomap | 9q33.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B4E1W8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3371 | TNC | LZE2T | Human | Esophagus | ESCC | 5.57e-03 | 1.64e+00 | 0.082 |
3371 | TNC | LZE4T | Human | Esophagus | ESCC | 1.39e-23 | 2.02e+00 | 0.0811 |
3371 | TNC | LZE7T | Human | Esophagus | ESCC | 1.23e-02 | -5.73e-01 | 0.0667 |
3371 | TNC | LZE22D1 | Human | Esophagus | HGIN | 5.44e-03 | -5.51e-01 | 0.0595 |
3371 | TNC | LZE24T | Human | Esophagus | ESCC | 1.00e-04 | -5.08e-01 | 0.0596 |
3371 | TNC | P9T-E | Human | Esophagus | ESCC | 1.63e-15 | 1.15e+00 | 0.1131 |
3371 | TNC | P10T-E | Human | Esophagus | ESCC | 8.75e-49 | 1.80e+00 | 0.116 |
3371 | TNC | P11T-E | Human | Esophagus | ESCC | 5.31e-21 | 2.62e+00 | 0.1426 |
3371 | TNC | P12T-E | Human | Esophagus | ESCC | 2.64e-45 | 2.21e+00 | 0.1122 |
3371 | TNC | P15T-E | Human | Esophagus | ESCC | 2.19e-34 | 2.29e+00 | 0.1149 |
3371 | TNC | P16T-E | Human | Esophagus | ESCC | 1.89e-13 | -5.68e-01 | 0.1153 |
3371 | TNC | P17T-E | Human | Esophagus | ESCC | 1.42e-12 | 1.56e+00 | 0.1278 |
3371 | TNC | P19T-E | Human | Esophagus | ESCC | 1.60e-02 | 1.31e+00 | 0.1662 |
3371 | TNC | P21T-E | Human | Esophagus | ESCC | 1.06e-61 | 3.52e+00 | 0.1617 |
3371 | TNC | P22T-E | Human | Esophagus | ESCC | 2.21e-05 | 3.17e-01 | 0.1236 |
3371 | TNC | P24T-E | Human | Esophagus | ESCC | 2.80e-05 | 9.41e-01 | 0.1287 |
3371 | TNC | P26T-E | Human | Esophagus | ESCC | 6.75e-36 | 1.87e+00 | 0.1276 |
3371 | TNC | P27T-E | Human | Esophagus | ESCC | 2.27e-02 | 9.22e-01 | 0.1055 |
3371 | TNC | P28T-E | Human | Esophagus | ESCC | 4.61e-03 | 4.61e-03 | 0.1149 |
3371 | TNC | P30T-E | Human | Esophagus | ESCC | 6.96e-04 | 2.02e+00 | 0.137 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007149626 | Esophagus | HGIN | cellular response to external stimulus | 71/2587 | 320/18723 | 2.77e-05 | 7.19e-04 | 71 |
GO:190165420 | Esophagus | HGIN | response to ketone | 48/2587 | 194/18723 | 3.17e-05 | 8.12e-04 | 48 |
GO:003166820 | Esophagus | HGIN | cellular response to extracellular stimulus | 56/2587 | 246/18723 | 9.05e-05 | 1.97e-03 | 56 |
GO:004873225 | Esophagus | HGIN | gland development | 88/2587 | 436/18723 | 1.34e-04 | 2.71e-03 | 88 |
GO:000164917 | Esophagus | HGIN | osteoblast differentiation | 50/2587 | 229/18723 | 5.88e-04 | 8.30e-03 | 50 |
GO:009730520 | Esophagus | HGIN | response to alcohol | 54/2587 | 253/18723 | 6.46e-04 | 8.87e-03 | 54 |
GO:003166920 | Esophagus | HGIN | cellular response to nutrient levels | 47/2587 | 215/18723 | 8.20e-04 | 1.07e-02 | 47 |
GO:003166726 | Esophagus | HGIN | response to nutrient levels | 89/2587 | 474/18723 | 1.41e-03 | 1.64e-02 | 89 |
GO:000150316 | Esophagus | HGIN | ossification | 75/2587 | 408/18723 | 5.49e-03 | 4.49e-02 | 75 |
GO:006145819 | Esophagus | HGIN | reproductive system development | 78/2587 | 427/18723 | 5.53e-03 | 4.52e-02 | 78 |
GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
GO:0031668111 | Esophagus | ESCC | cellular response to extracellular stimulus | 168/8552 | 246/18723 | 4.93e-13 | 2.23e-11 | 168 |
GO:0031669110 | Esophagus | ESCC | cellular response to nutrient levels | 148/8552 | 215/18723 | 4.58e-12 | 1.76e-10 | 148 |
GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
GO:000758410 | Esophagus | ESCC | response to nutrient | 114/8552 | 174/18723 | 9.43e-08 | 1.56e-06 | 114 |
GO:0061458110 | Esophagus | ESCC | reproductive system development | 247/8552 | 427/18723 | 2.24e-07 | 3.42e-06 | 247 |
GO:004860818 | Esophagus | ESCC | reproductive structure development | 245/8552 | 424/18723 | 2.82e-07 | 4.14e-06 | 245 |
GO:004206027 | Esophagus | ESCC | wound healing | 243/8552 | 422/18723 | 4.62e-07 | 6.25e-06 | 243 |
GO:000164918 | Esophagus | ESCC | osteoblast differentiation | 140/8552 | 229/18723 | 1.63e-06 | 1.95e-05 | 140 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0451018 | Prostate | BPH | Focal adhesion | 85/1718 | 203/8465 | 1.17e-12 | 2.28e-11 | 1.41e-11 | 85 |
hsa0516513 | Prostate | BPH | Human papillomavirus infection | 111/1718 | 331/8465 | 6.15e-09 | 7.81e-08 | 4.83e-08 | 111 |
hsa0415112 | Prostate | BPH | PI3K-Akt signaling pathway | 104/1718 | 354/8465 | 2.07e-05 | 1.55e-04 | 9.61e-05 | 104 |
hsa0451212 | Prostate | BPH | ECM-receptor interaction | 28/1718 | 89/8465 | 8.33e-03 | 2.64e-02 | 1.64e-02 | 28 |
hsa0451025 | Prostate | Tumor | Focal adhesion | 84/1791 | 203/8465 | 3.44e-11 | 6.69e-10 | 4.15e-10 | 84 |
hsa0516522 | Prostate | Tumor | Human papillomavirus infection | 110/1791 | 331/8465 | 1.31e-07 | 1.51e-06 | 9.36e-07 | 110 |
hsa0415122 | Prostate | Tumor | PI3K-Akt signaling pathway | 105/1791 | 354/8465 | 7.42e-05 | 5.30e-04 | 3.28e-04 | 105 |
hsa0451035 | Prostate | Tumor | Focal adhesion | 84/1791 | 203/8465 | 3.44e-11 | 6.69e-10 | 4.15e-10 | 84 |
hsa0516532 | Prostate | Tumor | Human papillomavirus infection | 110/1791 | 331/8465 | 1.31e-07 | 1.51e-06 | 9.36e-07 | 110 |
hsa0415132 | Prostate | Tumor | PI3K-Akt signaling pathway | 105/1791 | 354/8465 | 7.42e-05 | 5.30e-04 | 3.28e-04 | 105 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
TNC | SDC4 | TNC_SDC4 | TENASCIN | Breast | ADJ |
TNC | SDC1 | TNC_SDC1 | TENASCIN | Breast | DCIS |
TNC | SDC4 | TNC_SDC4 | TENASCIN | Breast | DCIS |
TNC | ITGAV_ITGB6 | TNC_ITGAV_ITGB6 | TENASCIN | Breast | Healthy |
TNC | SDC1 | TNC_SDC1 | TENASCIN | Breast | Healthy |
TNC | SDC4 | TNC_SDC4 | TENASCIN | Breast | Healthy |
TNC | SDC4 | TNC_SDC4 | TENASCIN | Breast | Precancer |
TNC | ITGA8_ITGB1 | TNC_ITGA8_ITGB1 | TENASCIN | Cervix | ADJ |
TNC | SDC1 | TNC_SDC1 | TENASCIN | Cervix | ADJ |
TNC | SDC4 | TNC_SDC4 | TENASCIN | Cervix | ADJ |
TNC | ITGA8_ITGB1 | TNC_ITGA8_ITGB1 | TENASCIN | Cervix | CC |
TNC | ITGA9_ITGB1 | TNC_ITGA9_ITGB1 | TENASCIN | Cervix | CC |
TNC | ITGAV_ITGB6 | TNC_ITGAV_ITGB6 | TENASCIN | Cervix | CC |
TNC | SDC1 | TNC_SDC1 | TENASCIN | Cervix | CC |
TNC | SDC4 | TNC_SDC4 | TENASCIN | Cervix | CC |
TNC | ITGA8_ITGB1 | TNC_ITGA8_ITGB1 | TENASCIN | Cervix | Healthy |
TNC | SDC1 | TNC_SDC1 | TENASCIN | Cervix | Healthy |
TNC | SDC4 | TNC_SDC4 | TENASCIN | Cervix | Healthy |
TNC | ITGA8_ITGB1 | TNC_ITGA8_ITGB1 | TENASCIN | Cervix | Precancer |
TNC | SDC1 | TNC_SDC1 | TENASCIN | Cervix | Precancer |
Page: 1 2 3 4 5 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNC | SNV | Missense_Mutation | c.2848N>G | p.Thr950Ala | p.T950A | P24821 | protein_coding | tolerated(0.95) | benign(0.009) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
TNC | SNV | Missense_Mutation | rs200602864 | c.5528N>A | p.Arg1843His | p.R1843H | P24821 | protein_coding | tolerated(0.12) | benign(0.103) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TNC | SNV | Missense_Mutation | rs200465690 | c.6026C>T | p.Ala2009Val | p.A2009V | P24821 | protein_coding | deleterious(0.01) | benign(0.364) | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNC | SNV | Missense_Mutation | c.2905N>C | p.Lys969Gln | p.K969Q | P24821 | protein_coding | deleterious(0.05) | benign(0.299) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TNC | SNV | Missense_Mutation | novel | c.2027N>G | p.Ser676Cys | p.S676C | P24821 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-A8-A09B-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
TNC | SNV | Missense_Mutation | rs748790119 | c.1496N>A | p.Arg499His | p.R499H | P24821 | protein_coding | deleterious(0.05) | benign(0) | TCGA-AC-A23E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
TNC | SNV | Missense_Mutation | rs146024320 | c.5174N>T | p.Ser1725Leu | p.S1725L | P24821 | protein_coding | deleterious(0.01) | possibly_damaging(0.869) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNC | SNV | Missense_Mutation | novel | c.2213N>T | p.Ala738Val | p.A738V | P24821 | protein_coding | deleterious(0.02) | possibly_damaging(0.777) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNC | SNV | Missense_Mutation | rs781414339 | c.3764A>G | p.Glu1255Gly | p.E1255G | P24821 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNC | SNV | Missense_Mutation | novel | c.4108N>T | p.Ala1370Ser | p.A1370S | P24821 | protein_coding | tolerated(0.51) | benign(0.345) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3371 | TNC | DRUGGABLE GENOME, FIBRINOGEN | CHEMBL2109584 | F16SIP 131I | ||
3371 | TNC | DRUGGABLE GENOME, FIBRINOGEN | F-16-131I | |||
3371 | TNC | DRUGGABLE GENOME, FIBRINOGEN | NEURADIAB | |||
3371 | TNC | DRUGGABLE GENOME, FIBRINOGEN | CHEMBL2109582 | 81C6 131I | ||
3371 | TNC | DRUGGABLE GENOME, FIBRINOGEN | 8H9 | 8H9 131I | ||
3371 | TNC | DRUGGABLE GENOME, FIBRINOGEN | CHEMBL1743077 | TENATUMOMAB | ||
3371 | TNC | DRUGGABLE GENOME, FIBRINOGEN | F-16-IL-2 fusion protein | |||
3371 | TNC | DRUGGABLE GENOME, FIBRINOGEN | CHEMBL2109583 | F16IL2 |
Page: 1 |